Viridian Therapeutics, Inc. (VRDN)
|Net Income (ttm)||-30.09M|
|Trading Day||February 26|
|Day's Range||16.12 - 17.15|
|52-Week Range||4.66 - 25.67|
With the trading day about half over, the broad markets had pulled back on Monday.
miRagen Therapeutics Announces Company Name Change to Viridian Therapeutics and New Executive Appointments, Including Expansion of Leadership Team
BOULDER, Colo., Jan. 19, 2021 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a development-stage biotechnology company, today announced its name change to Viridian Therapeutics...
Viridian Therapeutics, a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high-unmet medical need. Its four lead product candidates include cobomarsen, an inhibitor of miR-155 for treating various blood cancers, such as cutaneous T-cell lymphoma, adult T-cell lymphoma/leukemia, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia; Remlarsen, a replacement for miR-29, a microRNA that is found... [Read more...]
|Stock Exchange |
|Ticker Symbol |
In 2019, VRDN's revenue was $4.46 million, a decrease of -46.80% compared to the previous year's $8.39 million. Losses were -$41.87 million, 28.0% more than in 2018.